FMCNA’s Novalung ECMO System Receives the US FDA’s Approval for Acute Respiratory and Cardiopulmonary Failure

Shots:

• The US FDA has cleared the Novalung system which eliminates the need for mechanical ventilation by pumping a person’s blood through an oxygenator for gas exchange
• Novalung is the first extracorporeal membrane oxygenation (ECMO), approved to provide for more than 6hrs. of use as extracorporeal life support with its anticipated availability in the US in mid-2020
• The Novalung ECMO system works by pumping and oxygenating a patient’s blood, reducing the stress on the damaged heart and lungs. Novalung is a portable therapy solution designed to improve clinical outcomes and accommodate various clinical care settings such as ICU, OT, cardiac catheterization labs and emergency departments

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Fresenius Medical Care North America